1 / 8

Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors (nRTIs)

Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors. Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors (nRTIs). 69 Insertion Complex (affects all nRTIs currently approved by the US FDA). Multi-nRTI Resistance.

jacob
Télécharger la présentation

Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors (nRTIs)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors (nRTIs) 69 Insertion Complex (affects all nRTIs currently approved by the US FDA) Multi-nRTI Resistance 151 Complex (affects all nRTIs currently approved by the US FDA except tenofovir) Multi-nRTI Resistance Thymidine Analogue-Associated Mutations (TAMs; affect all nRTIs currently approved by the US FDA other than emtricitabine and lamivudine) Multi-nRTI Resistance

  2. Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors (cont’d) Abacavir Didanosine Emtricitabine Lamivudine Stavudine Tenofovir Zidovudine

  3. Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors (cont’d) Nonnucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs) Efavirenz Etravirine Nevirapine Rilpivirine

  4. Mutations in the Protease Gene Associated With Resistance to Protease Inhibitors Atazanavir +/-ritonavir Darunavir/ritonavir Fosamprenavir/ritonavir Indinavir/ritonavir Lopinavir/ritonavir

  5. Mutations in the Protease Gene Associated With Resistance to Protease Inhibitors (cont’d) Nelfinavir Saquinavir/ritonavir Tipranavir/ritonavir

  6. Mutations in the Envelope Gene Associated With Resistance to Entry Inhibitors Enfuvirtide Maraviroc User Notes available at www.iasusa.org

  7. Mutations in the Integrase Gene Associated With Resistance to Integrase Strand Transfer Inhibitors Dolutegravir Elvitegravir Raltegravir

  8. IAS–USA Drug Resistance Mutations Group 2017 Update of the Drug Resistance Mutations in HIV-1 Annemarie M. Wensing, MD, PhD; Vincent Calvez, MD, PhD; Huldrych F. Günthard, MD; Victoria A. Johnson, MD; Roger Paredes, MD, PhD; Deenan Pillay, MD, PhD; Robert W. Shafer, MD; Douglas D. Richman, MD Top Antivir Med. 24(4). Updates available at www.iasusa.org. IAS–USA is a not-for-profit, HIV clinical specialist–education organization. It is entirely different from and not affiliated with the International AIDS Society.

More Related